Skip to content
Screener

Zymeworks ZYME Operating Income

Operating Income at other companies

Amgen logo
AmgenAMGN
$3.51B+32.3%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$15.55M-8.0%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
-$82.77M-31.2%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
-$62.78M-26.6%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$8.59M+1.7%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$16.78M+124%

Other financials

Income statement

See full
Revenue$4.6M-90.6%
Net income-$45.0M-2,043%
EPS (diluted)-$0.62-2,167%

Balance sheet

See full
Cash & equivalents$179.4M+82.6%
Total debt$16.0M-14.3%
Total equity$80.4M-76.0%
Total assets$397.0M-2.8%

Cash flow

See full
Operating cash flow-$31.9M-365%
CapEx$216.0K+1,250%
Free cash flow-$31.9M-376%

Valuation

See full
Market cap$1.7B+83.2%
Enterprise value$1.54B+81.1%
P/S45.8×+38.3×

Profitability

See full
Operating margin-419%-518pp
Net margin-404%-489pp
FCF margin-324.7%-366pp

Returns & leverage

See full
Return on equity-72.3%-117pp
Debt / equity0.2×+0.1×
Current ratio6.3×-1.4×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Zymeworks’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001937653-26-000047
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development27,43534,44961,89270,187
General and administrative19,33514,95134,40431,936
Total operating expenses46,77049,40096,296102,123
Loss from operations(42,180)(674)(89,298)(26,287)
Other (expense) income:
Interest income3,2873,4265,9986,850
Interest expense related to sale of future royalties(6,595)(8,661)
Other income (expense), net196(621)316(572)

Item 1. Financial Statements

FAQ

What is Zymeworks's operating income?
Zymeworks (ZYME) reported operating income of -$42.18M in Q2 2026.
How has Zymeworks's operating income changed year-over-year?
Zymeworks's operating income decreased by 6158.2% year-over-year, from -$674K to -$42.18M.
What is the long-term trend for Zymeworks's operating income?
Over 3 years (2022 to 2025), Zymeworks's operating income has grown at a -10.8% compound annual growth rate (CAGR), from $130.53M to -$92.55M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Zymeworks's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude